论文部分内容阅读
目的观察急性心肌梗死尿激酶溶栓治疗的临床疗效。方法急性心肌梗死患者142例,按是否符合溶栓治疗条件分为尿激酶溶栓治疗组70例和常规治疗组72例,并对胸痛缓解、冠状动脉再通率、住院病死率等方面进行比较。结果冠脉再通率溶栓治疗组高于常规组,胸痛发生率、心衰发生率、心律失常发生率、住院病死率,溶栓组低于常规组(P均<0.05),休克发生率两组比较差异无统计学意义(P>0.05)。结论尿激酶溶栓治疗法对急性心肌梗死的临床治疗效果较好,简单易行,安全有效。
Objective To observe the clinical efficacy of urokinase thrombolysis in patients with acute myocardial infarction. Methods 142 patients with acute myocardial infarction were divided into thrombolytic therapy group (n = 70) and conventional treatment group (n = 72) according to whether they were eligible for thrombolytic therapy or not, and chest pain relief, coronary recanalization rate and hospital mortality were compared . Results The rate of coronary recanalization thrombolytic therapy was higher than that of the conventional group. The incidence of chest pain, the incidence of heart failure, the incidence of arrhythmia, hospital mortality, thrombolytic group were lower than those in the conventional group (P <0.05) There was no significant difference between the two groups (P> 0.05). Conclusions Urokinase thrombolytic therapy is effective in clinical treatment of acute myocardial infarction. It is simple, safe and effective.